Fabry Disease - Xconomy

by in

Entry	Author	Date	Location
East Coast Life Sciences Roundup: Blend, Amicus, Vertex, & More	Catherine Arnst	12/21/12	Boston
Amicus-GlaxoSmithkline Drug for Fabry Disease Fails Clinical Trial	Catherine Arnst	12/20/12	New York
Amicus Counts on “Chaperone” Tech to Enhance Rare Disease Treatments	Arlene Weintraub	01/11/12	New York
Shire Finds Big Value in Rare Diseases, and a Strong Growth Path for its Boston Unit	Arlene Weintraub	05/12/11	New York
Edimer, Third Rock’s Bet on Rare Diseases, Aims to Begin First Human Tests	Ryan McBride	03/15/11	Boston
Report: Fabry Patients Sue Genzyme and Mt. Sinai Medical School	Ryan McBride	03/11/11	Boston
Xconomy Readers Set $20B Pricetag on Genzyme—Is That Too Rich for Sanofi-Aventis?	Ryan McBride	07/29/10	Boston
Genzyme in “Tough Spot” with Icahn Proxy Challenge—CEO Termeer Courting Key Shareholders	Ryan McBride	05/13/10	Boston
Genzyme Starts Fabrazyme Trial	Luke Timmerman	10/15/08	Boston
Page 1 of 1

Xconomy National